Exome sequencing in Parkinson's disease

Authors

  • JM Bras,

    Corresponding author
    1. Department of Molecular Neuroscience, Institute of Neurology, University College of London, London, UK
      Jose M. Bras, Department of Molecular Neuroscience, Institute of Neurology, UCL, London WC1N 3BG, UK.
      Tel.: +44 (0) 207 837 3611 x 83936;
      fax: +44 (0) 207 833 1016;
      e-mail: j.bras@ion.ucl.ac.uk
    Search for more papers by this author
  • AB Singleton

    1. Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
    Search for more papers by this author

Jose M. Bras, Department of Molecular Neuroscience, Institute of Neurology, UCL, London WC1N 3BG, UK.
Tel.: +44 (0) 207 837 3611 x 83936;
fax: +44 (0) 207 833 1016;
e-mail: j.bras@ion.ucl.ac.uk

Abstract

Bras JM, Singleton AB. Exome sequencing in Parkinson's disease.

Exome sequencing is rapidly becoming a fundamental tool for genetics and functional genomics laboratories. This methodology has enabled the discovery of novel pathogenic mutations causing mendelian diseases that had, until now, remained elusive. In this review, we discuss not only how we envisage exome sequencing being applied to a complex disease, such as Parkinson's disease, but also what are the known caveats of this approach.

Ancillary